Chronic kidney disease (CKD) and hypertension.
Conditions
Brief summary
Time to the first occurrence of any of the components of the composite of: 1. ≥ 50% sustained decline in eGFR 2. Onset of kidney failure: • Sustained eGFR < 15 mL/min/1.73 m2 or • Chronic dialysis treatment or • Receiving a kidney transplant or • Death with a renal primary cause (death due to kidney failure when dialysis is not given) 3. CV death
Detailed description
Change from baseline in UACR., Change from baseline in mean SBP., Time to the first occurrence of any of the components of the composite of: • CV death • HF with and without hospitalisation • MI • Stroke, CV death., Death.
Interventions
Sponsors
Astrazeneca AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to the first occurrence of any of the components of the composite of: 1. ≥ 50% sustained decline in eGFR 2. Onset of kidney failure: • Sustained eGFR < 15 mL/min/1.73 m2 or • Chronic dialysis treatment or • Receiving a kidney transplant or • Death with a renal primary cause (death due to kidney failure when dialysis is not given) 3. CV death | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in UACR., Change from baseline in mean SBP., Time to the first occurrence of any of the components of the composite of: • CV death • HF with and without hospitalisation • MI • Stroke, CV death., Death. | — |
Countries
Belgium, Bulgaria, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Slovakia, Spain, Sweden
Outcome results
None listed